Abstract
Despite undisputable benefits conventional pacemaker therapy is associated with some
specific complications due to the subcutaneous pacemaker placement and the transvenous
leads. Recently 2 miniaturized leadless pacemakers, Nanostim (St. Jude Medical) and
Micra (Medtronic), that can be fully implanted into the right ventricle using steerable
delivery systems entered clinical application. These systems may – additionally to
the cosmetic aspects – overcome the problems of conventional pacing. Initial clinical
data for the Nanostim system indicate appropriate safety profile and performance.
However it is still not completely known, which new complications may arise specific
to the new technology, implantation and explantation. Large studies are underway to
answer these questions.
